Follow
Carles Escriu
Carles Escriu
Medical Oncology Consultant, Clatterbridge Cancer Centre, University of Liverpool
Verified email at nhs.net
Title
Cited by
Cited by
Year
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
PE Postmus, KM Kerr, M Oudkerk, S Senan, DA Waller, J Vansteenkiste, ...
Annals of oncology 28, iv1-iv21, 2017
16952017
Diverse epigenetic strategies interact to control epidermal differentiation
KW Mulder, X Wang, C Escriu, Y Ito, RF Schwarz, J Gillis, G Sirokmany, ...
Nature cell biology 14 (7), 753-763, 2012
1692012
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response
A Haragan, JK Field, MPA Davies, C Escriu, A Gruver, JR Gosney
Lung Cancer 134, 79-84, 2019
1282019
ESMO Guidelines Committee Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
PE Postmus, KM Kerr, M Oudkerk, S Senan, DA Waller, J Vansteenkiste, ...
Ann Oncol 28 (4), iv1-iv21, 2017
972017
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA
M Tsuboi, W Weder, C Escriu, C Blakely, J He, S Dacic, Y Yatabe, L Zeng, ...
Future Oncology 17 (31), 4045-4055, 2021
922021
Early-stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines
PE Postmus, KM Kerr, M Oudkerk, S Senan, DA Waller, J Vansteenkiste
Ann Oncol 28 (suppl 4), 1-21, 2017
412017
Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance
LS Schwartzberg, H Horinouchi, D Chan, S Chernilo, ML Tsai, D Isla, ...
NPJ precision oncology 4 (1), 15, 2020
262020
A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer
AY Warren, CE Massie, K Watt, K Luko, F Orafidiya, LA Selth, ...
Oncogene 38 (7), 1136-1150, 2019
232019
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)
S Popat, HA Jung, SY Lee, MJ Hochmair, SH Lee, C Escriu, MK Lee, ...
Lung Cancer 162, 9-15, 2021
212021
Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the …
J Lester, C Escriu, S Khan, E Hudson, T Mansy, A Conn, S Chan, ...
BMC cancer 21 (1), 515, 2021
202021
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker …
GL Banna, O Cantale, S Muthuramalingam, J Cave, C Comins, ...
International Immunopharmacology 110, 108985, 2022
172022
Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis
RA De Mello, C Escriu, P Castelo-Branco, PL Cabral, G Mountzios, ...
Oncotarget 9 (14), 11805, 2018
102018
A Cancer Research UK two-stage multicenter phase II study of imatinib in the treatment of patients with c-kit positive metastatic uveal melanoma (ITEM).
PD Nathan, E Marshall, CT Smith, M Bickerstaff, C Escriu, M Marples, ...
Journal of Clinical Oncology 30 (15_suppl), 8523-8523, 2012
102012
P03. 02 Neoadjuvant osimertinib with/without chemotherapy vs chemotherapy for EGFR mutated resectable NSCLC: NeoADAURA
M Tsuboi, W Weder, C Escriu, C Blakely, J He, S Dacic, Y Yatabe, L Zeng, ...
Journal of Thoracic Oncology 16 (3), S258, 2021
92021
Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the …
M Sallam, H Wong, C Escriu
BMC Pulmonary Medicine 19, 1-8, 2019
92019
Genomic alterations and the incidence of brain metastases in advanced and metastatic non-small cell lung cancer: a systematic review and meta-analysis
CS Gillespie, MA Mustafa, GE Richardson, AM Alam, KS Lee, DM Hughes, ...
Journal of Thoracic Oncology, 2023
72023
The effects of GCSF primary prophylaxis on survival outcomes and toxicity in patients with advanced non-small cell lung cancer on first-line chemoimmunotherapy: a Sub-analysis …
S Anpalakhan, P Huddar, R Behrouzi, A Signori, J Cave, C Comins, ...
International Journal of Molecular Sciences 24 (2), 1746, 2023
62023
Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer
C Escriu, JK Field
Journal of Thoracic Disease 8 (9), 2357, 2016
52016
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis
S Anpalakhan, P Huddar, R Behrouzi, A Signori, J Cave, C Comins, ...
Frontiers in Oncology 13, 1163768, 2023
32023
Treatment beyond four cycles of first line platinum and etoposide chemotherapy in real-life patients with stage IV small cell lung cancer: A retrospective study of the …
M Sallam, H Wong, C Escriu
Annals of Oncology 29, viii598, 2018
22018
The system can't perform the operation now. Try again later.
Articles 1–20